NEW YORK (GenomeWeb) – B Braun Medical US and Tuebingen, Germany-based CeGaT today announced the launch of a US company offering next-generation sequencing-based diagnostics.

The new firm called B Braun CeGaT is based in B Braun Medical's headquarters in Bethlehem, Pa. and will offer CeGaT's diagnostic panels for evaluating all the genes that are associated with a patient's phenotype. The technology was launched in 2010 and is being made available in the US with the establishment of B Braun CeGaT.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.